Gerresheimer Faces a Defining Period as Financial Deadlines Loom

Gerresheimer's 2025 audit delay triggers SDAX exclusion and credit covenant breach. The firm negotiates with lenders, sells assets, and books major impairments as its share price plummets.

The coming weeks are set to be critical for Gerresheimer. The company is confronting a perfect storm of regulatory deadlines, financial reviews, and urgent negotiations with its lenders. At the core of the issue is the packaging specialist's inability to publish its audited financial statements for 2025 by the mandated deadline of March 31.

A Consequence of Delay: SDAX Exclusion and Lender Talks

This failure to file certified results has a direct and severe consequence: automatic expulsion from the SDAX index. A more pressing concern, however, lies in the breach of information covenants within Gerresheimer's existing credit agreements. The company is currently engaged in discussions with its creditors to secure extended filing deadlines. The goal is to prevent lenders from calling in loans or imposing stricter, more costly terms.

The delay stems from an ongoing special audit. A second external auditing firm is examining business transactions from 2024 and 2025, with a particular focus on "bill-and-hold" agreements. These accounting practices involve recognizing revenue before physical delivery of goods. Management now targets a publication date for the 2025 accounts in June 2026.

Strategic Asset Sale and Substantial Impairments

To shore up its financial structure, Gerresheimer has initiated the sale of its US subsidiary, Centor Inc. This unit, which specializes in packaging for prescription medicines, is described as profitable. Investment bank Morgan Stanley is managing the sale process, with a completion goal still set for 2026.

Simultaneously, the company's financials are being weighed down by significant impairment charges totaling between 220 and 240 million euros. These writedowns are primarily linked to technology projects at the Sensile Medical subsidiary and the glass plant in Chicago Heights, which is scheduled to close by the end of 2026. In a move to conserve capital, the dividend for 2025 has already been slashed to the legal minimum of 0.04 euros per share.

An Uncertain Path Forward

Looking ahead to 2026, Gerresheimer's management has provided guidance forecasting revenue of 2.3 to 2.4 billion euros and a modestly positive free cash flow. However, in the absence of the audited 2025 figures, investors find this outlook difficult to contextualize or trust fully.

The market's current sentiment is reflected in the share price, which trades around 20 euros. This represents a dramatic fall from levels seen just a year ago, when the stock was valued above 70 euros. The outcome of the ongoing creditor negotiations, expected within the next few weeks, is likely to be the primary catalyst for the next significant move in the share price, determining whether Gerresheimer can navigate its way toward stability.